Transaction #17316 · Form 4 · 0001395064-25-000172
Ovid Therapeutics Inc. · Conversion · Common Stock
Ovid Therapeutics Inc. · Transacted December 8, 2025 · Filed December 9, 2025
What does this filing report?
An SEC Form 4 filing for Ovid Therapeutics Inc. records a conversion involving Common Stock on December 8, 2025. The reported quantity was 1,250,000. The filing date is December 9, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- Ovid Therapeutics Inc.
- Company CIK
- 0001636651
- Security type
- Non-derivative
- Acquisition type
- Conversion · Code C
- Quantity acquired
- 1,250,000
- Reported price
- 0
- Reference value
- 0
- Currency
- Currency not specified
- Ownership
- Indirect
- Holdings after transaction
- 7,000,000
- Ownership description
- See Explanation of Responses
- SEC acceptance time
- Dec 9, 2025, 9:19 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- TAKEDA PHARMACEUTICAL CO LTD ↗
10% owner
CIK 0001395064
- Takeda Pharmaceuticals U.S.A., Inc. ↗
10% owner
CIK 0001716229
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Each share of Series A convertible preferred stock (the "Preferred Stock") of Ovid Therapeutics Inc. ("Ovid") was convertible into 1,000 shares of Ovid's common stock at any time at the election of TPUSA. On December 8, 2025, TPUSA elected to convert all 1,250 shares of Preferred Stock held by TPUSA.
- F2
- The reportable securities are directly held by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"). TPUSA is a direct subsidiary of Takeda Pharmaceuticals International AG. Takeda Pharmaceuticals International AG is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. As such, Takeda may be deemed to have indirect beneficial ownership of the securities held by TPUSA.
- F3
- The Preferred Stock had no expiration date.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.